English | Español

Regulatory
+ Regulatory
Patient Daily | May 7, 2023

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
+ Technology/Innovation
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
+ Community
Patient Daily | May 7, 2023

Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
+ Technology/Innovation
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
+ Regulatory
Patient Daily | May 7, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
+ Community
Patient Daily | May 7, 2023

Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
+ Technology/Innovation
Patient Daily | May 7, 2023

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
+ Community
Patient Daily | May 7, 2023

Integra LifeSciences To Host Investor Day On May 4, 2023

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation